Literature DB >> 8741814

Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.

D K Nagi1, V Mohamed Ali, S K Jain, S Walji, J S Yudkin.   

Abstract

In order to study the plasminogen activator inhibitor activity (PAI-1) in subjects at different risk of non-insulin-dependent diabetes and ischaemic heart disease we examined 89 subjects with diet controlled NIDDM (49 Caucasian, 40 Asian), 29 with impaired glucose tolerance (IGT) (13 Caucasian, 16 Asian), and 149 with normal glucose tolerance (67 Caucasian, 82 Asian). Diabetes was diagnosed by WHO criteria and highly specific, monoclonal antibody-based assays were used to measure insulin, intact proinsulin, and des 31,32 proinsulin. Subjects with NIDDM were significantly more obese, had more central distribution of obesity, higher fasting plasma specific insulin concentrations (NIDDM median 74 pmol l-1 vs IGT 41 pmol l-1, p < 0.01 and vs normals 34 pmol l-1, p < 0.001) and higher PAI-1 activity than normals and those with IGT (NIDDM 23.0 +/- 6.9 vs IGT 16.8 +/- 5.0, p < 0.001 and vs normals 17.1 +/- 6.9 AU ml-1, p < 0.001). However, PAI-1 activity was not significantly different between Asian and Caucasian normals (17.5 +/- 7.3 vs 16.5 +/- 6.4 AU ml-1, p = ns) and diabetic (22.8 +/- 7.3 vs 23.1 +/- 6.6 AU ml-1, p = ns) subjects. In addition to relationships with obesity and plasma triglyceride, PAI-1 activity, after controlling for age, sex, body mass index, and waist-hip ratio, was related to fasting insulin (partial r = 0.22, p < 0.001), intact proinsulin (partial r = 0.36, p < 0.001), and des 31,32 proinsulin concentrations (partial r = 0.33, p < 0.001) as measured by highly specific assays. The association of PAI-1 with diabetes was weakened but remained statistically significant (p = 0.042) after controlling for age, sex, ethnicity, obesity, plasma triglyceride, and all insulin-like molecules. We conclude that, although PAI-1 activity is raised in subjects with diet-treated NIDDM, it is normal in subjects with IGT and non-diabetic Asians, populations at high risk of NIDDM and ischaemic heart disease. Raised PAI-1 activity may play an important role in the pathogenesis of macrovascular disease in subjects with NIDDM, but is unlikely to explain excess risk of ischaemic heart disease in Asians and those with impaired glucose tolerance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8741814     DOI: 10.1002/(SICI)1096-9136(199601)13:1<59::AID-DIA2>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  8 in total

1.  Improved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention Study.

Authors:  H Hämäläinen; T Rönnemaa; A Virtanen; J Lindström; J G Eriksson; T T Valle; P Ilanne-Parikka; S Keinänen-Kiukaanniemi; M Rastas; S Aunola; M Uusitupa; J Tuomilehto
Journal:  Diabetologia       Date:  2005-10-05       Impact factor: 10.122

2.  Similar cardiovascular risk factor profile in screen-detected and known type 2 diabetic subjects.

Authors:  Poul Erik Heldgaard; Jan Erik Henriksen; Johannes J Sidelmann; Niels de Fine Olivarius; Volkert D Siersma; Jørgen B Gram
Journal:  Scand J Prim Health Care       Date:  2011-03-28       Impact factor: 2.581

Review 3.  Type 2 diabetes and cardiovascular risk in the UK south Asian community.

Authors:  A H Barnett; A N Dixon; S Bellary; M W Hanif; J P O'hare; N T Raymond; S Kumar
Journal:  Diabetologia       Date:  2006-07-18       Impact factor: 10.122

Review 4.  Impact and mechanism for oxidized and glycated lipoproteins on generation of fibrinolytic regulators from vascular endothelial cells.

Authors:  Garry X Shen
Journal:  Mol Cell Biochem       Date:  2003-04       Impact factor: 3.396

5.  Sitagliptin Improves the Impaired Acute Insulin Response during a Meal Tolerance Test in Japanese Patients with Type 2 Diabetes Mellitus: A Small-Scale Real-World Study.

Authors:  Tsuyoshi Ohkura; Youhei Fujioka; Keisuke Sumi; Risa Nakanishi; Hideki Shiochi; Naoya Yamamoto; Kazuhiko Matsuzawa; Shoichiro Izawa; Hiroko Ohkura; Masahiko Kato; Shin-Ichi Taniguchi; Kazuhiro Yamamoto
Journal:  Diabetes Ther       Date:  2014-06-03       Impact factor: 2.945

6.  Role of ACE and PAI-1 Polymorphisms in the Development and Progression of Diabetic Retinopathy.

Authors:  Saba Saleem; Aisha Azam; Sundus Ijaz Maqsood; Irfan Muslim; Shaheena Bashir; Nosheen Fazal; Moeen Riaz; Syeda Hafiza Benish Ali; Muhammad Khizar Niazi; Mazhar Ishaq; Nadia Khalida Waheed; Raheel Qamar; Maleeha Azam
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

Review 7.  Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies.

Authors:  James Yarmolinsky; Natália Bordin Barbieri; Tobias Weinmann; Patricia K Ziegelmann; Bruce B Duncan; Maria Inês Schmidt
Journal:  Sci Rep       Date:  2016-01-27       Impact factor: 4.379

Review 8.  A Serpin With a Finger in Many PAIs: PAI-1's Central Function in Thromboinflammation and Cardiovascular Disease.

Authors:  Gael B Morrow; Claire S Whyte; Nicola J Mutch
Journal:  Front Cardiovasc Med       Date:  2021-04-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.